Pfizer (PFE) and Alliance Foundation Trials said Thursday that results from a phase 3 trial of the drug Ibrance showed that adding it to standard-of-care therapies extended median progression-free survival by over 15 months in patients with metastatic breast cancer.
The study involved patients with hormone receptor-positive, human epidermal growth factor receptor 2-positive metastatic breast cancer, according to a joint statement.
It showed a median progression-free survival of 44.3 months for 261 patients treated with Ibrance in combination with anti-HER2 therapy and endocrine therapy, compared with a median PFS of 29.1 months for 257 patients treated with anti-HER2 therapy and endocrine therapy alone, Pfizer and AFT said.
Pfizer is providing funding support for the trial, which is sponsored by AFT and cancer research groups in the US, Germany, Italy, Spain, Australia, and New Zealand.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。